Attorneys involved in Zantac litigation may be divided on the significance of the U.S. Food and Drug Administration’s decision calling on drugmakers to pull the heartburn medication from the market, but all agree the move highlights what appears to be a growing unease over its safety.

The FDA announced it was asking manufacturers to withdraw all prescription and over-the-counter Zantac from the market over concerns that a potentially carcinogenic molecule in the drug may build up over time if the medication is stored above room temperature. Many retailers already had removed Zantac from store shelves.